All
FDA Approves Radiation Therapy for Outpatient Setting in Liver Cancer Subtype
March 19th 2021Patients with this liver cancer subtype do not need to be hospitalized to receive this treatment and, according to the agent’s manufacturer, Boston Scientific, can typically receive the therapy in approximately an hour during an outpatient procedure.
The Basics of Multiple Myeloma
March 18th 2021In this episode of the “CURE® Talks Cancer” podcast, we’re honoring Multiple Myeloma Awareness Month by speaking with Dr. Andrew Yee, about the signs and symptoms of this rare form of cancer, what the current treatment paradigm looks like and what advice he has for newly diagnosed patients.
Emerging Therapies Show Promise in Treating Metastatic Breast Cancer
March 16th 2021An expert discusses the potential that several novel therapies hold in treating metastatic breast cancer, including PARP inhibitors, immunotherapy and antibody drug conjugates. Each therapy type has an FDA-approved option to potentially provide patients with better outcomes and quality of life.
FDA Fast Track of Novel Drug May Open Doors for Certain Patients with Non-Small Cell Lung Cancer
March 15th 2021The FDA’s fast track designation to poziotinib for use in previously treated patients with non-small cell lung cancer whose disease harbors a certain genetic mutation, may open the doors to an accelerated approval.
The Future of Adoptive Cellular Therapy in Lung Cancer
March 15th 2021In the field of lung cancer, a number of current studies evaluating the efficacy of adoptive cellular therapies may one day offer patients with non-small cell lung cancer a “high risk, high reward” treatment option, according to Dr. Ben Creelan of the Moffitt Cancer Center.
FDA to Evaluate Status of 6 Cancer Drug Indications That Were Granted Accelerated Approvals
March 14th 2021The FDA announced that a special committee will review the indications of several cancer drugs that were granted accelerated approval as confirmatory trials showed they failed to demonstrate efficacy.